ES2087162T3 - Tratamiento de la diabetes insulino-resistente. - Google Patents

Tratamiento de la diabetes insulino-resistente.

Info

Publication number
ES2087162T3
ES2087162T3 ES90913512T ES90913512T ES2087162T3 ES 2087162 T3 ES2087162 T3 ES 2087162T3 ES 90913512 T ES90913512 T ES 90913512T ES 90913512 T ES90913512 T ES 90913512T ES 2087162 T3 ES2087162 T3 ES 2087162T3
Authority
ES
Spain
Prior art keywords
insulin
treatment
resistant diabetes
diabetes
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90913512T
Other languages
English (en)
Inventor
Angus Carstairs Maccuish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2087162T3 publication Critical patent/ES2087162T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE UTILIZA EL FACTOR DE CRECIMIENTO TIPO INSULINA (IGF) PARA EL TRATAMIENTO DE DIABETIS TIPO A RESISTENTE A LA INSULINA, REDUCIENDO LOS NIVELES DE GLUCOSA. EL TRATAMIENTO ES APLICABLE AL SINDROME DE MENDENHALL, SINDROME DE WERNER, LEPRACAUNISMO, DIABETIS LIPOATROPICA Y OTRAS LIPOATROPIAS.
ES90913512T 1989-09-08 1990-09-10 Tratamiento de la diabetes insulino-resistente. Expired - Lifetime ES2087162T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898920381A GB8920381D0 (en) 1989-09-08 1989-09-08 Treatment of insulin-resistant diabetes

Publications (1)

Publication Number Publication Date
ES2087162T3 true ES2087162T3 (es) 1996-07-16

Family

ID=10662782

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90913512T Expired - Lifetime ES2087162T3 (es) 1989-09-08 1990-09-10 Tratamiento de la diabetes insulino-resistente.

Country Status (11)

Country Link
US (1) US5674845A (es)
EP (1) EP0490955B1 (es)
JP (1) JP2513360B2 (es)
AT (1) ATE138578T1 (es)
AU (1) AU642665B2 (es)
CA (1) CA2066227A1 (es)
DE (1) DE69027217T2 (es)
DK (1) DK0490955T3 (es)
ES (1) ES2087162T3 (es)
GB (1) GB8920381D0 (es)
WO (1) WO1991003253A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
WO1993025226A1 (en) * 1992-06-08 1993-12-23 Kabi Pharmacia Ab Use of growth factor igf-i and/or igf-ii
EP0642350A4 (en) * 1993-01-25 1995-06-28 Beth Israel Hospital PROCESS FOR MODIFICATION, DIAGNOSIS AND SCREENING OF IGF-I SENSITIVE CELL BARRIER CHARACTERISTICS.
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
WO1998027813A1 (en) * 1996-12-24 1998-07-02 Amur Pharmaceuticals, Inc. Methods for treating insulin resistance and identifying patients at risk for the disease
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6627746B1 (en) 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
HUP0103396A3 (en) * 1998-07-08 2002-05-28 Kirin Amgen Inc Wilmington Powdery preparation for mucosal administration containing polymeric medicine
US6902898B2 (en) * 1998-11-16 2005-06-07 National Institute Of Advanced Industrial Science And Technology Human derived bradeion proteins, DNA coding for the proteins, and uses thereof
JP3141107B2 (ja) * 1998-11-16 2001-03-05 工業技術院長 ヒト由来ブラディオン蛋白質、それをコードするｄｎａ及びそれらの使用
JP3971108B2 (ja) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
IL145597A0 (en) 1999-04-08 2002-06-30 Genentech Inc Composition based on oppositely-charged polypeptides
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
EP1358209B1 (en) 2001-02-09 2006-12-27 Genentech, Inc. Crystallization of igf-1
CA2702192A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20200376028A1 (en) * 2017-04-10 2020-12-03 Yoram Palti Methods and Compounds for Treating Diabetes
KR20230090336A (ko) * 2020-10-13 2023-06-21 베타바이브 리미티드 당뇨병 및 관련된 대사성 질환을 치료하기 위한 방법 및 화합물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU624596B2 (en) * 1987-12-16 1992-06-18 Genesis Systems Corporation Method and system for detection and treatment of premenstrual syndrome
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1

Also Published As

Publication number Publication date
DE69027217T2 (de) 1996-10-02
WO1991003253A1 (en) 1991-03-21
ATE138578T1 (de) 1996-06-15
CA2066227A1 (en) 1991-03-09
GB8920381D0 (en) 1989-10-25
US5674845A (en) 1997-10-07
EP0490955A1 (en) 1992-06-24
AU6358090A (en) 1991-04-08
JPH05504547A (ja) 1993-07-15
DE69027217D1 (de) 1996-07-04
JP2513360B2 (ja) 1996-07-03
EP0490955B1 (en) 1996-05-29
AU642665B2 (en) 1993-10-28
DK0490955T3 (da) 1996-06-24

Similar Documents

Publication Publication Date Title
ES2087162T3 (es) Tratamiento de la diabetes insulino-resistente.
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
NO892303D0 (no) Stabilisert fgf-sammensetning og fremstilling derav.
SE8703625D0 (sv) New medical use
IE882583L (en) Treatment of wounds
DE3650499D1 (de) Verwendung von "Cartilage-inducing Factor" (CIF) zur Behandlung von hemato- oder lymphopoietischen Krankheiten
DE3669103D1 (de) Ibuprofen enthaltendes arzneimittel.
DE59010810D1 (de) Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
NO2002009I2 (no) Tiotropium
FI905003A0 (fi) Glykosaminoglykan modifierat protein.
AU8090087A (en) The use of 3-deoxy-thymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
IE822064L (en) Composition containing human insulin and c-peptide
DE3781488D1 (de) Pharmazeutische zusammensetzung, enthaltend 2',3'-dideoxycytidin-2'-en(2',3'-dideoxy-2',3'-didehydrocytidin) zur behandlung von mit retrovirus infizierten patienten.
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
IE882529L (en) Platinum Coordination Compound
KR0158672B1 (en) Injectable ready-to-use solutions containing an antitumour anthracycline glycoside
KR920703050A (ko) 골형성 촉진제
IE791183L (en) Phenylpropynylamino benzoic acids
JPS6463342A (en) Stabilization of glutathione-containing composition
KR880000094A (ko) 위염치료제
SE7706192L (sv) Antimikrobielle paste
KR910007540A (ko) 혈구 감소 장해의 예방ㆍ치료제
Rayfield Can strict glucose control prevent infections in diabetics?.
KR890001549A (ko) 위염 치료제

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0490955

Country of ref document: ES